Spreading immune-reactions in esophageal cancer patients who were given cancer vaccine and whose tumors co-express additional antigens

• Project/Area Number: 24591939
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Mie University
• Principal Investigator: KAGEYAMA Shinichi 三重大学, 医学(系)研究科(研究院), 教授 (80194695)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000); Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2012: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: がんワクチン / 食道癌

Outline of Final Research Achievements

Clinical trials of cancer vaccine, including CHP-MAGE-A4 protein vaccine and CHP-NY-ESO-1 protein vaccine, were conducted for esophageal cancer patients. Tumor samples were analyzed for tumor antigen expressions. Serum samples of pre-vaccine and post-vaccine time points were analyzed for protein microarray reactions and ELISA of MAGE-A4 and NY-ESO-1 antigens. We assessed immune-spreading phenomenon across other antigens that were not immunized.

Research Products

• [Journal Article] Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer (2015)
  • Author(s): Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, Sugino S, Ueda S, Ishikawa T, Kokura S, Naota H, Ohishi K, Shiraishi T, Inoue N, Tanabe M, Kidokoro T, Yoshioka H, Tomura D, Nukaya I, Mineno J, Takesako K, Katayama N, Shiku H.
  • Journal Title: Clinical Cancer Research Volume: in press Issue: 10 Pages: 2268-2277
  • DOI: 10.1158/1078-0432.ccr-14-1559
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine (2014)
  • Author(s): Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E, Kageyama S, Shiku H, Mori M, Doki Y.
  • Journal Title: Vaccine Volume: 32 Issue: 45 Pages: 5901-5907
  • DOI: 10.1016/j.vaccine.2014.09.002
  • Peer Reviewed
• [Journal Article] Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients (2013)
  • Author(s): Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H
  • Journal Title: Journal of translational medicine Volume: 5;11 Issue: 1 Pages: 246-246
  • DOI: 10.1186/1479-5876-11-246
  • Peer Reviewed
• [Journal Article] Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes (2013)
  • Author(s): Hirayama M, Nishikawa H, Nagata Y, Tsuji T, Kato T, Kageyama S, Ueda S, Sugiyama D, Hori S, Sakaguchi S, Ritter G, Old LJ, Gnjatic S, and Shiku H
  • Journal Title: Eur J Immunol Volume: 43 (4) Issue: 4 Pages: 989-1000
  • DOI: 10.1002/eji.201242800
  • Peer Reviewed
• [Presentation] 食道癌に対する免疫療法―がんワクチンと免疫細胞療法― (2014)
  • Author(s): 影山愼一
  • Organizer: 第12回日本臨床腫瘍学会学術集会
  • Place of Presentation: 福岡国際会議場（福岡市）
  • Year and Date: 2014-07-19
  • Invited
• [Presentation] TCR-gene engineered T cell transfer as a treatment for refractory esophageal cancer (2014)
  • Author(s): 影山愼一
  • Organizer: 第12回日本臨床腫瘍学会学術集会
  • Place of Presentation: 福岡国際会議場（福岡市）
  • Year and Date: 2014-07-18
  • Invited
• [Presentation] Immune responses and survival benefits of esophageal cancer patients vaccinated with NY-ESO-1(CHP-NY-ESO-1); P1 trial (2013)
  • Author(s): 影山愼一
  • Organizer: 第11回日本臨床腫瘍学会総会
  • Place of Presentation: 仙台市
• [Presentation] 大学発トランスレーショナルリサーチの経験から (2012)
  • Author(s): 影山愼一、珠玖 洋
  • Organizer: 第71回日本癌学会学術総会
  • Place of Presentation: 札幌市
• [Presentation] NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) provides dose-dependent effects on immune responses and survival benefits for recurrent esophageal cancer patients.
  • Author(s): 影山愼一
  • Organizer: The European Cancer Congress 2013（2013年欧州がん会議）
  • Place of Presentation: アムステルダム（オランダ）